跳至主導覽 跳至搜尋 跳過主要內容

Proteomics analysis of empagliflozin in patients without diabetes or overt heart failure from empagliflozin and cardiac remodeling in people without diabetes CardioLink-7 randomized clinical trial

  • Wei Siang Chen
  • , Ning I. Yang
  • , Subodh Verma
  • , Min Hui Liu
  • , Kun Yi Chien
  • , Chia Wei Chen
  • , Adrian Quan
  • , Hwee Teoh
  • , Andrew T. Yan
  • , Kim A. Connelly
  • , Yu Hsiang Juan
  • , Ching Wen Chang
  • , C. David Mazer
  • , Chao Hung Wang*
  • *此作品的通信作者
  • Chang Gung Memorial Hospital
  • University of Toronto
  • St Michael's Hospital
  • Chang Gung University

研究成果: 期刊稿件 › 文章 › 同儕審查

摘要

Background – Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce cardiovascular and cardiorenal events in people across the spectrum of heart failure. Using proteomics analysis, this study investigated the potential benefits of SGLT2 inhibitors in primary prevention at a protein level in patients without diabetes or heart failure. Methods – This is a sub-study of the EMPA-HEART 2 CardioLink-7 trial, which randomized people without diabetes or clinically overt heart failure but with risk factors for adverse cardiac remodeling to empagliflozin (10 mg/day) or placebo for 6 months. Blood samples were collected during the randomization visit and at the 6-month follow-up visit for proteomics analysis. Our investigation involved two phases of approach: discovery and verification. Results – Samples from individuals assigned to empagliflozin (n = 21) and placebo (n = 22) (median baseline N-terminal pro-B-type natriuretic peptide levels: 33.9 and 78.4 pg/ml, respectively) were analyzed. In the discovery phase, 28 of 1622 proteins fulfilled our threshold for being differentially expressed at 6 months. Ten proteins were verified, including calmodulin-like protein 5, desmoplakin, hornerin, peroxiredoxin-2, macrophage colony-stimulating factor 1 receptor, endosialin, high-temperature requirement serine protease A1, immunoglobulin epsilon heavy chain, proteasome subunit beta type-5, and cerebellin-4. Compared to the placebo group, the expression of these proteins from baseline to 6 months was all significantly decreased in the empagliflozin group. Their functions involved ion channel signaling, fibrosis, oxidative stress, inflammation, apoptosis, immune response, proteolysis, and neuromodulation. Conclusion – Empagliflozin modified multiple biologically relevant pathways in the nondiabetes and non-heart failure setting. These findings should be considered hypothesis-generating and warrant validation in larger, adequately powered studies.

原文英語
文章編號e00358
頁(從 - 到)e00358
頁數9
期刊Cardiovascular Endocrinology and Metabolism
卷15
發行號2
DOIs
出版品狀態已出版 - 06 2026

文獻附註

Publisher Copyright:
© 2026 The Author(s). Published by Wolters Kluwer Health, Inc.

UN SDG

此研究成果有助於以下永續發展目標

  1. SDG3 健康與福祉
    SDG3 健康與福祉

指紋

深入研究「Proteomics analysis of empagliflozin in patients without diabetes or overt heart failure from empagliflozin and cardiac remodeling in people without diabetes CardioLink-7 randomized clinical trial」主題。共同形成了獨特的指紋。

引用此